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A B S T R A C T
Although trastuzumab is a successful targeted therapy for breast cancer patients with tumors express-
ing HER2 (ERBB2), many patients eventually progress to drug resistance. Here, we identiﬁed subpathways
differentially expressed between trastuzumab-resistant vs. -sensitive breast cancer cells, in conjunction
with additional transcriptomic preclinical and clinical gene datasets, to rigorously identify overexpressed,
resistance-associated genes. From this approach, we identiﬁed 32 genes reproducibly upregulated in
trastuzumab resistance. 25 genes were upregulated in drug-resistant JIMT-1 cells, which also downregulated
HER2 protein by >80% in the presence of trastuzumab. 24 genes were downregulated in trastuzumab-
sensitive SKBR3 cells. Trastuzumab sensitivity was restored by siRNA knockdown of these genes in the
resistant cells, and overexpression of 5 of the 25 genes was found in at least one of ﬁve refractory
HER2 + breast cancer. In summary, our rigorous computational approach, followed by experimental val-
idation, signiﬁcantly implicate ATF4, CHEK2, ENAH, ICOSLG, and RAD51 as potential biomarkers of trastuzumab
resistance. These results provide further proof-of-concept of our methodology for successfully identify-
ing potential biomarkers and druggable signal pathways involved in tumor progression to drug resistance.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Introduction
Worldwide, breast cancer kills over 521,000 women annually, as-
sociated with over 1.7 million new cases [1]. Approximately 25% of
cases express the human epidermal growth factor receptor-2 (HER2,
ERBB2), a 185-kDa transmembrane tyrosine kinase. HER2 has no
known ligand, but plays a major role in the progression of breast
and other cancers [2]. A humanized monoclonal antibody against
HER2, trastuzumab (Herceptin®), was approved for the treatment
of HER2-positive breast cancer in 1998 [3]. The HERA (Herceptin
Adjuvant) phase III trial showed that in early HER2-positive breast
cancer patients, one-year trastuzumab therapy following surgery
resulted in 32% greater disease-free survival [4]. However, an ad-
ditional 1 year of adjuvant trastuzumab therapy showed no
additional beneﬁt [5]. While the therapy is initially effective against
metastatic breast cancer, drug-resistant relapse is almost univer-
sal [6]. Due to the cost vs. beneﬁt of trastuzumab, and the emerging
study of other HER2-targeted therapies, drug-response-predictive
biomarkers are strongly needed.
A number of studies have now reported various possible cellular/
molecular mechanisms of trastuzumab resistance, largely from
comparing sensitive vs. resistant breast cancer cell lines. Of these
is overactivity of the mitogenic PI3K/Akt pathway. In particular,
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activating mutations in PI3K and loss of its antagonist, PTEN, have
been identiﬁed in both preclinical [7,8] and clinical [9,10] studies
of trastuzumab-resistant breast cancer. However, another study,
examining both trastuzumab-treated and -untreated patients over
three years, found no association of resistance with either of
these PI3K pathway members [11]. Other reported resistance con-
tributors include DARPP, HSP90, cytosolic sequestration of the cell
cycle inhibitor CDKN1B (p27KIP1), and downregulated tubulin III
[3,12,13].
In addition to the above-described intracellular signal media-
tors, several cell surface transmembrane proteins and kinases have
been implicated in trastuzumab resistance via either indirect or direct
interaction with HER2. These include the hyaluronate receptor CD44,
MUC4, c-MET, integrins α6β1 and α6β4, and HER2 heterodi-
merization with other EGFR family members [3]. As CD44 expres-
sion combined with low or absent CD24 has been reported to
demarcate breast “cancer stem cells” [14] it has also been hypoth-
esized that trastuzumab resistance may arise from a failure to
eradicate tumor progenitors [3]. Analogously, the cancer stem cell-
associated epithelial-to-mesenchymal transition has also been
implicated in trastuzumab resistance [15].
In the current study, rather than examining HER2 signal effec-
tors or pathways in isolation, we used a systems biology [16–18]
approach, and applied our recently established subpathway iden-
tiﬁcation [16] and network permutationmethod [17], which resulted
in identiﬁcation of 32 upregulated KEGG subpathway genes common
to two preclinical and two clinical datasets. This discovery method
allows the consideration of pathway “edges” as well as individual
“nodes” [16]. The roles of these genes in trastuzumab resistance were
experimentally validated by their upregulation in refractory
HER2 + breast cancer cells and tumors. Based on these results, we
believe our subpathway and network permutation approach is ef-
fective for identifying biomarker genes and pathways responsible
for resistance to trastuzumab and other targeted, antineoplastic
agents.
Materials and Methods
Trastuzumab-resistant network and its reproducibly upregulated,
resistance-associated genes
To delineate a trastuzumab resistance network, we applied an association rule
[16], based on gene expression and KEGG pathways, to identify all possible subsets
of signaling pathways. This rule was applied to a preclinical dataset [GEO: GSE15043]
composed of two BT474 drug-sensitive parent cells and eight BT474 daughter
subclones selected for resistance by continuous growth in 0.2 and 1.0 μM trastuzumab
[19]. The subsets, i.e., subpathways, included not only nodes but also edges such as
activation or inhibition among the nodes [16]. The subpathways associated with drug
resistance are represented by a network (Fig. 1), visualized using Cytoscape [20]. This
network consisted of 4502 subpathways, with 916 gene entries. The statistical sig-
niﬁcance of the network was measured by “the mean correlation over all edges in
the network”, henceforth designated as “r” [17,21], to describe interactions between
entities, rather than a single entity [22]. A correlation of an edge was calculated from
the Pearson correlation coeﬃcient of the expressions between two neighboring nodes.
The r value was obtained from the mean of the correlations of all the edges. With
the network topology conserved, we randomly permuted the node labels in the
network to obtain the null distribution of the statistic r. The true mean correlation
prior to permutation was set to r0. We performed 5000 permutations, and the em-
pirical p-value was calculated from Pr(r > r0).
Reproducible gene entries belonging to the network were identiﬁed using
multiple trastuzumab-resistant preclinical ([GEO: GSE15376] [23] [ArrayExpress:
E-TABM-157] [24]) and resistance-associated clinical datasets. We also
compared Herceptin-nonresponsive and -responsive cells from the two preclinical
datasets. The HER2-positive control cells, SKBR3 and BT474 are Herceptin-
responsive, while two HER2-negative control cell lines, MCF7 and MDA-MB-231
are Herceptin-nonresponsive [25]. Additional clinical datasets were used to
assess survival associated with gene expression proﬁles in HER2 + recurrent
breast cancer from The Cancer Genome Atlas (TCGA) [26] dataset under the
heading “Breast Invasive Carcinoma (TCGA, Nature 2012)” provided by cBioPortal
[27], including 47 disease-free HER2 + patients vs. 7 recurred HER2 + patients,
and the Netherlands Cancer Institute dataset contained 25 disease-free
HER2 + patients vs. 24 recurrent HER2 + patients [28]. These four trastuzumab
resistance-associated upregulated gene intersections (Fig. 2) resulted in the iden-
tiﬁcation of 32 genes (Table 1) with their corresponding KEGG pathways listed in
Appendix S1: Supplementary Table S1, including “Hallmarks of Cancer” in Appendix
S1: Supplementary Table S2.
We performed overall survival analyses, based on 66 TCGA HER2 + breast
cancer patients. The 66 patients were selected based on PAM50 classiﬁcation
that was annotated in the dataset TCGA_BRCA_exp_HiSeqV2-2014-05-02
(column PAM50Call_RNAseq in ﬁle clinical_data) from the UCSC Cancer Genomics
Browser (https://genome-cancer.ucsc.edu) [29]. The expression subset of the 32
genes among the 66 patients was extracted from the dataset, and we divided the
patients into two groups (high, low) in terms of the expression of each gene in the
subset: gene expression greater than the median expression of the patient was
denoted as “high;” otherwise it was denoted “low.” Subsequently, we performed
log-rank tests between the two groups for each gene. We also generated Kaplan–
Meier curves for the gene MMP9 as well as PER2, a gene of interest due to the
recent emergence of circadian rhythm dysfunction as a risk factor for breast cancer
[30].
Procurement and processing of tumor tissues
Patients consented to the use of the tissue specimens for research purposes, as
approved by the Institutional Review Board of National Cancer Center, Republic of
Korea (Ilsan, Korea). Histologic classiﬁcation and tumor stage were reviewed by a
pathologist in the Department of Pathology at the National Cancer Center. In-
cluded in our analysis were eight breast tumor samples. Clinical characteristics of
6 out of the 8 patients, including Herceptin sensitivity, are summarized in Table 2
(Appendix S1: Supplementary Fig. S1A and S1B).
Cell lines and reagents
We obtained human breast cancer cell lines SKBR3 and JIMT-1 cells from the
American Type Culture Collection (ATCC, Manassas, VA, USA) and The German Col-
lection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). ATCC
and DSMZ uses short tandem repeat proﬁling to authenticate all cell lines [31]. Re-
agents used on SKBR3 and JIMT-1 breast cancer cells, including a HER2 monoclonal
antibody, were purchased from Abgent (San Diego, CA).
Cell culture
SKBR3 and JIMT-1 human breast cancer cell line studies were performed within
six months of cell resuscitation. SKBR3 cells were grown in McCoy’s 5A medium
(Sigma-Aldrich, St. Louis, MO) and JIMT-1 cells were grown in DMEM (Hyclone, Logan,
UT) with 10% FBS (Hyclone) at 37 °C in 5% CO2. Cells (2.5 × 105) were seeded and
grown under normoxic conditions to 70–80% conﬂuency, and then incubated with
or without 10 μg/ml trastuzumab [32] for up to 4 days, according to the required
time study.
Western blotting
Cells grownwith or without 10 μg/ml trastuzumabwere harvested, washed twice
in phosphate-buffered saline solution, lysed, and subjected to Western blot, as we
previously described [33]. The blots were quantiﬁed using Image Lab software (Bio-
Rad, Hercules, CA).
Real-time RT-PCR analysis
Total RNA was isolated from cell lysates using Isol-RNA Lysis Reagent (5PRIME,
Hamburg, Germany) and processed with ReverTra Ace® qPCR RT Master Mix with
gDNA Remover Kit (Toyobo, Osaka, Japan) to synthesize cDNA. Quantitative PCR was
conducted using iQ™ SYBR® Green Supermix (Bio-Rad), according to the manufa-
cturer’s protocol, using a CFX384 TouchTM Real-Time PCR Detection System (Bio-
Rad). Primer sequences were obtained from RTPrimerDB (http://rtprimerdb.org/),
designed via GenScript Real-time PCR (TaqMan) Primer Design (https://
www.genscript.com/ssl-bin/app/primer) or manually designed, as indicated in
Appendix S1: Supplementary Table S3. Measurements of all 32 genes were initial-
ly analyzed. Twenty-ﬁvemet the following quality standards: (1) No template control
of primer sets must read a null (no signal detected) Ct value. (2) Resulting Ct value
must be between 32 and 37. Normalization procedures and folds-change were carried
out using β-actin, as we have previously reported [33] using the 2(-delta-delta C(T))
method as the internal reference [34]. P-values for tumor samples were calculated
between each trastuzumab-resistant patient sample with each of the trastuzumab-
responding patient sample. Trastuzumab-resistant patient samples with statistically
signiﬁcantly (i.e. p < 0.05 with all three trastuzumab-responding patients)
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increased gene expression have been indicated with an asterisk (*). All measure-
ments were performed in triplicate.
siRNA knockdown of trastuzumab-treated cells
4000 (SKBR3) or 2000 (JIMT-1) cells were plated in 384-well plates (Greiner Bio-
One, Monroe, NC). Cells were plated in triplicate and 6 images were taken per well.
siRNA was purchased from Thermo Scientiﬁc (Waltham, MA) and incubated at a con-
centration of 50 nM. 0.5 μl of DharmaFECT1 was used per well. After 48 hr siRNA
treatment, cells were treated for 48 hr with 10 μg/ml trastuzumab, ﬁxed (4% paraform-
aldehyde), stained with HCS Cellmask (Molecular Probes, Eugene, OR), and nuclei
stained with Draq5 (Cell Signaling Technology, Danvers, MA) for viability counting.
OPERA (Opera High Content Screening System, PerkinElmer, Waltham, MA) was used
for imaging and cell counting. PRISM (Version 5) software was used for analysis of
the siRNA data.
Results
Trastuzumab-resistance network and resistance-associated genes
To identify candidate biomarkers or “signatures” of trastuzumab-
resistant breast cancer, we applied a systems biology approach, using
multiple datasets. First, we obtained a trastuzumab-resistance global
network by applying our published systems biology approach [16]
to BT474 drug-sensitive parent cells and four BT474 resistant daugh-
ter subclones [GEO: GSE15043] [19]. The network consisted of 129
edges and 916 resistance-related genes. The permutation-based test
of the network was statistically signiﬁcant (p-value 0.000; Appendix
S1: Supplementary Fig. S2). The network (Fig. 1) revealed various
Fig. 1. The subpathway-network relating to the trastuzumab resistance.We applied our previous systems biology approach [16] to trastuzumab-resistant cells versus trastuzumab-
responsive cells [19] in order to obtain all the subpathways relating to resistance. The network consisting of the 4502 subpathways is represented. The network implicated
in resistance shows not only multiple pathways but also complex cross-talk among the pathways. The yellow shaded oval indicates “crosstalk” from which upregulated
genes represented in Appendix S1: Supplementary Fig. S3A. In this ﬁgure, we noted 19 KEGG pathways involved in resistance; the pathways are provided in detail in Appendix
S1: Supplementary Fig. S3.
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signaling pathways, e.g., tight junctions, axon guidance, etc., not
previously implicated in trastuzumab resistance. Also, the
pathways closely interconnected by “crosstalk” genes (light
yellow-shaded ovals in Fig. 1; for upregulated, red-dotted cross-
talk genes, refer to expanded view in Appendix S1: Supplementary
Fig. S3A).
As shown in Fig. 1, the total network comprised 19 distinct KEGG
pathways (expanded views in Appendix S1: Supplementary
Fig. S3B–F), including pathways related to the “hallmarks of cancer”
[35] (Appendix S1: Supplementary Table S2). These computa-
tional ﬁndings likely reﬂect clonal selection of a tumor cell
subpopulation utilizing signal pathways autonomous of the drug-
speciﬁc target (in this case, HER2), similar to breast or prostate cancer
hormone independence [36,37].
Subsequently, we further explored reproducible gene entries be-
longing to the network throughout multiple trastuzumab-resistance
preclinical ([GEO: GSE15376] [23], [ArrayExpress: E-TABM-157]) [24]
and clinical datasets. In particular, the clinical datasets were in-
spected in terms of HER2-positive recurrent breast cancer vs.
extended disease-free survival, from The Cancer Genome Atlas [26]
and The Netherlands Cancer Institute [28]. Through analyzing these
datasets, we identiﬁed 32 genes which were upregulated in asso-
ciation with trastuzumab resistance.
Characteristics and clinical relevance of the 32 resistance-associated
genes and their associated pathways
As shown in Table 1, the 32 genes commonly upregulated in
trastuzumab resistance encode a diverse group of proteins, includ-
ing oncoproteins (TIAM1, FRAT1), signal transducers (STAT3, SMAD1),
and catenin family members of cadherin-binding proteins
(CTNNA1, JUP), in association with the “hallmarks” of cancer [35]
(Appendix S1: Supplementary Tables S1 and S2). Further, some
of these 32 genes reside in pathways previously implicated in
HER2 signaling, including MMP9 and MAPK10 [3,13,38,39],
as corroborated by our bioinformatics identiﬁcation of the MAPK,
TGF-beta, and Wnt KEGG pathway groups (Appendix S1:
Supplementary Fig. S3C–E). We also identiﬁed a guanine nucleo-
tide exchange factor gene, TIAM1, that in the brain, recruits α6β1,
an integrin thought to interfere with trastuzumab binding to HER2
[3]. Interestingly, we also identiﬁed PER2, a component gene of
the circadian clock oscillatory system regulated by p53. Circadian
clock dysfunction, another identiﬁed KEGG pathway, hsa04710
(Appendix S1: Supplementary Fig. S3B) has been recently linked
to breast carcinogenesis [40]. Overall survival analysis for all the
32 genes was performed by log-rank test (Appendix S1:
Supplementary Table S4), and the two genes (PER2, MMP9) were
associated with prognosis (Appendix S1: Supplementary Fig. S4A
and B).
We also identiﬁed PTPRF, encoding a protein phosphatase, in the
trastuzumab resistance dataset, in similarity to previous studies im-
plicating another phosphatase, DARPP, in trastuzumab resistance
(through the PI3K pathway) [12]. Interestingly, PTPRF is regulated
by EGFR signaling [41].
We also identiﬁed several mediators of inﬂammatory responses,
including STAT3, ICOSLG, and RPS6KA5 (cytokine-cytokine receptor
interactions, KEGG pathway hsa04672, Appendix S1: Supplementary
Fig. S3E). Inﬂammation has been linked to breast cancer, largely in
association with overexpression of speciﬁc cytokines secreted by
inﬁltrating monocytes [42].
Experimental validation of overexpression of the 25 least-studied
trastuzumab-resistance genes in cell lines and tumor specimens
For further characterization of the 32 genes, we used two
well-established breast cancer cell models of trastuzumab
resistance: the trastuzumab-resistant cell line JIMT-1 and the
-sensitive cell line SKBR3 [32,43]. Drug sensitivity and HER2
expression of these cells was conﬁrmed by time-dependent
growth curves, showing only a 15% loss of viability of
JIMT-1 resistant cells, following a four-day culture in 10 μg/ml
trastuzumab. The widely used SKBR3 cell line, by contrast,
exhibited >30% loss of viability after four days of trastuzumab
treatment, compared to no treatment (Fig. 3A), in agreement
with a previous study demonstrating 10 μg/ml trastuzumab as a
“saturable” dose effective for SKBR3 sensitivity [32]. Moreover,
JIMT-1 cells demonstrated >90% downregulation of HER2 protein,
after each day of trastuzumab treatment, and by day 4, even
untreated JIMT-1 cells showed 60% downregulation (Fig. 3B). In the
same time period, SKBR3 cells showed negligible changes in
HER2 expression. These results agree with previous studies showing
HER2 internalization or “shedding” of its extracellular domain
(thus precluding antibody binding and/or halting inhibition of
normal HER2 pathway signaling) as mechanisms of trastuzumab
resistance [3,43].
Fig. 2. Reproducibly upregulated genes, common among multiple datasets, and val-
idation of the drug resistance network. The network of subpathways inferred from
GSE15043 was compared to two other preclinical trastuzumab resistance datasets
([GEO: GSE15376] [23] and [ArrayExpress: ETABM-157] [24]) and two clinical datasets
(the TCGA [26] and the Netherlands Cancer Institute (NKI) [28]) to establish a vali-
dated predictor gene set. The comparison result (blue box in the Venn diagram)
consists of 32 genes commonly upregulated in trastuzumab resistance. Each set in
the Venn diagram represents commonly upregulated genes (resistance-related)
between its corresponding dataset and the network genes. The Venn diagram was
generated by Venny (bioinfogp.cnb.csic.es/tools/venny/).
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Of the 32 genes 25 genes were acceptable according to the
qRT-PCR quality control condition (Materials and Methods, Real-
time RT-PCR analysis). As noted above, Fig. 3B demonstrated that
the resistance of JIMT-1 cells associated with downregulation of
HER2 in the presence of trastuzumab, in a time-dependent manner.
Thus, we hypothesized that SKBR3 cells, having an intact HER2
signal transduction pathway (thus amenable to trastuzumab block-
ade), would differentially express the 25 resistance-correlated
genes in the presence of trastuzumab. After 24 hr trastuzumab
treatment, the 25 genes were downregulated in SKBR3 cells, and
upregulated in JIMT-1 cells (Fig. 3C). After 48 hr trastuzumab
treatment, however, profound effects on gene expression were
demonstrated, with greater downregulation of 24 of the 25
resistance-associated genes in SKBR3 cells, concomitant with
upregulation, with signiﬁcance, ARHGEF12, EGF, ENAH, ICOSLG,
TICAM1, and TPM1 in trastuzumab-resistant JIMT-1 cells (Fig. 3D,
heat map in Appendix S1: Supplementary Fig. S5). These results
suggest that the expression of these genes plays a signiﬁcant role
in trastuzumab resistance, in conjunction with downregulation of
the HER2 protein.
As shown in Fig. 4, siRNA knock-down of each speciﬁc gene in
JIMT-1 cells restored trastuzumab sensitivity in 27 out of 32 genes,
and loss of HER2 degradation, 48 hr after trastuzumab treatment
(data not shown).
Finally, we examined expression of the 25 out of 32 genes in
6–8 clinical specimens of HER2-positive tumors. Three were
Table 1
List of 32 trastuzumab resistance-associated genes. The genes in italic were ﬁltered out to further experimental validation due to quality control (see Materials and Methods).
Gene Location Gene product/function
ARHGEF12 11q23.3 Rho guanine nucleotide exchange factor; interacts with IGF1R
ATF4 22q13.1 Activating transcription factor; regulates glucose homeostasis
CCL22 17q11.2 Monocyte chemotactic protein; role in inﬂammation
CHEK2 22q12.1 Checkpoint kinase-2; blocks cell cycling upon DNA damage
CTNNA1 5q31.2 Cadherin-interacting protein (possible role in cell differentiation)
CYCS 7p15.3 Mitochondrial heme protein electron carrier; participates in apoptosis
EGF 4q25 Epidermal growth factor
EGLN2 19q13.2 Prolyl hydroxylase of hypoxia inducing factor-1
ENAH 1q42.12 Actin-associated protein; cytoskeleton remodeling
EPAS1 2p21-p16 Hypoxia-inducible transcription factor
FARP2 2p37.3 Guanine nucleotide exchange factor; cytoskeleton remodeling
FES 15q26.1 Feline sarcoma oncogene; tyrosine kinase
FRAT1 10q24.1 Inhibitor of GSK3 (likely oncogene)
ICOSLG (ICOSL) 21q22.3 Inducible T-cell co-stimulator ligand
JAM3 11q25 Cell-cell adhesion; mediator of angiogenesis
JUP 17q21 Junction Plakoglobin; binds cadherins; complexes to adherens junctions
LIMK2 22q12.2 LIM kinase-2; inhibits actin depolymerization; possible cytoskeleton reordering
MAPK10 4q22.1 Mitogen-activated protein kinase-10; growth signaling
MAPKAPK5 12q24.13 MAPK-activated protein kinase 5; HSP27 kinase (tumor suppressor)
MMP9 20q11.2 Degradation of extracellular matrix; cleavage of cell surface proteins
NFATC4 14q11.2 Nuclear factor of activated T cells (T-cell stimulator)
PER2 2q37.3 Period-2; component of the circadian core oscillator
PTPRF 1p32 Protein tyrosine phosphatase
RAD51 15q15.1 DNA repair protein; interacts with BRCA1 and BRCA2
RPS6KA5 14q31 Ribosomal Protein S6 Kinase-5; phosphorylates histones; role in inﬂammation
SMAD1 4q31 Transducer and transcriptional modulator of multiple signaling pathways
STAT3 17q21.31 Signal Transducer and Activator of Transcription 3; growth factor response
TIAM1 21q22.11 Guanine nucleotide exchange factor; modulates Rac1
TICAM1 (TRIF) 19p13.3 Toll-like receptor adaptor molecule 1; signal transducer
TJP2 9q13-q21 Tight Junction Protein-2; assembler and component of tight junction barrier
TPM1 15q22.1 Tropomyosin 1; involved in the contraction of striated and smooth muscles
VAMP4 1q24-q25 Vesicle-Associated Membrane Protein-4; role in exocytosis and secretion
Table 2
Trastuzumab-sensitive and -resistance tumors and patient clinical data. The ﬁrst three patients are trastuzumab-responsive and the last ﬁve patients are trastuzumab
non-responsive.
Patient
no.
Age at
biopsy
Initial diagnosis/
subtype
Initial
stage
Metastasis
in
Organ
biopsied
ER PR HER2 Ki67 Treatment Treatment outcome
1 66 8/1996/HER2 III 1/2013 Liver 8 4 3+ 36% Trastuzumab/docetaxel Improved and maintained on
trastuzumab monotherapy
2 46 7/2008/TN III 5/2010 Liver 8 8 3+ 32% Trastuzumab/anastrozole Improved
3 57 3/2007/LA III 11/2013 Liver 0 0 3+ 48% Trastuzumab/paclitaxel Improved
4 27 8/2012/HER2 II or III 2/2014 Liver 0 3 3+ 73% Trastuzumab adjuvant Retrying trastuzumab/paclitaxel
since metastasis
5 48 8/2009/HER2 III 2/2011 Liver 2 3 3+ 50% Trastuzumab adjuvant
and metastasis
Failed on every chemotherapeutic
agents (primary failure)
6 67 7/2000/HER2 III 10/2006 LN 0 0 3+ ND Trastuzumab/paclitaxel
for metastasis
Failed on trastuzumab monotherapy
7 47 1/2013/HER2 III 2/2013 Lungs 0 0 3+ 72% Trastuzumab/docetaxel Disease progression after 4th cycles
8 56 2/2012/HER2 III 4/2013 Lungs 0 0 3+ 39% Trastuzumab adjuvant Metastasis during adjuvant treatment
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B
Fig. 3. Validation of overexpression of 25 of the 32 genes in trastuzumab-resistant vs. -sensitive cells. SKBR3 and JIMT-1 cells (trastuzumab-sensitive, and -resistant, re-
spectively) were grown to 70% conﬂuency and treated with 10 μg/ml trastuzumab, with a portion of the cells harvested for isolation of total RNA after each day. (A) Cell
viability curves for JIMT-1 and SKBR3 cells grown for four days in 10 μg/ml trastuzumab. (B) Western blot of untreated vs. trastuzumab-treated JIMT-1 or SKBR3 cells fol-
lowing each 24 hr period. (C) Expression levels of 25 of the 32 genes after 24 hr culture with or without 10 μg/ml trastuzumab, as determined by qRT-PCR. (D) Expression
levels of the same 25 genes following 48 hr culture with or without 10 μg/ml trastuzumab, as determined by qRT-PCR. Control, β-actin, n = 3, *p < 0.05.
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trastuzumab-responsive patients and ﬁve unresponsive -patients
(see clinical characteristics for each patient, Table 2 and treatment
timelines in Appendix S1: Supplementary Fig. S1A and B). We note
that these biopsies were taken from metastatic lesions, and
HER2-positive metastatic breast cancer almost universally
progresses due to Herceptin resistance [3,6,44]. Of these, we
found ATF4, CHEK2, ENAH, ICOSLG and RAD51 to each be upregu-
lated in one or more trastuzumab-resistant tumors, with con-
current downregulation in responsive tumors (Fig. 5A–C). We
note that while patients 1–3 (Table 2) were classiﬁed as tras-
tuzumab-responsive, it is possible these patients may develop
resistance in the future (Appendix S1: Supplementary Fig. S1A)
[45–49].
Taken together, our rigorous bioinformatics approach re-
producibly implicated the expression of 32 genes in breast
cancer trastuzumab resistance. Overexpression of 25 of these
genes was validated in the trastuzumab-resistant cell line
JIMT-1. While JIMT-1 cells are HER2-positive, we note that in
SKBR3 (trastuzumab-sensitive) cells, trastuzumab is much more
inhibitory to HER2 heterodimerization with other EGFR
family members [50]. Moreover, HER2 was strongly down-
regulated by the presence of trastuzumab in JIMT-1 cells,
in stark contrast to SKBR3 cells. These ﬁndings lead us to hy-
pothesize that expression of the resistance-conferring genes
may allow autonomous HER2 downstream signaling in the
absence of HER2 tyrosine kinase activity. Moreover, it has also
been shown that trastuzumab sensitivity positively cor-
relates with levels of HER2 expression [44], and JIMT-1 cells
express only ~10% of the HER2 protein level of SKBR3 cells
(Fig. 3B).
Discussion
In this study, we used a subpathway-based and network per-
mutation method to analyze numerous preclinical and clinical
datasets to identify several KEGG pathways associated with HER2
D
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downstream signaling, including theMAPK,WNT, and TGF-beta cas-
cades (Fig. 1 and Appendix S1: Supplementary Table S1). We
previously demonstrated that this method was superior to stan-
dard Gene Set Enrichment Analysis (GSEA), based on its speciﬁc
consideration of cancer-related pathways [16]. In support of its ef-
fectiveness, subpathway-based analysis revealed several pathways
previously implicated in trastuzumab resistance in breast cancer [3].
Additionally, however, we found several pathways/processes not pre-
viously linked to Herceptin resistance, including circadian rhythms,
axon guidance, and tight junctions (Appendix S1: Supplementary
Tables S1 and S2). Of these, circadian dysregulation has been pre-
viously noted as a risk for breast cancer [40], while various axon
guidance molecules have been associated with various cancers,
perhaps due to their regulation of cytoskeleton structure [51].
Similarly, claudins, critical components of tight junctions, have been
proposed as an additional method for stratifying breast cancer
subtypes [52].
With regard to speciﬁc genes that might represent potential
Herceptin response biomarkers, examination of clinical speci-
mens validated overexpression of ATF4, CHEK2, ENAH, ICOSLG, and
RAD51 in trastuzumab resistance. We concede that our ﬁndings
our quite preliminary, with respect to the REMARK criteria for
biomarker clinical translation [53]. Nonetheless, there exists some
precedence for the respective pathways, composed of these genes,
in facilitating possible autonomy from HER2 signaling and evasion
of trastuzumab-associated, antibody-dependent cellular cytoxicity
[3]. In particular, trastuzumab was found to synergize with cis-
platin-induced DNA damage; consequently, one hypothesized
Fig. 4. Validation of trastuzumab-resistance reversible through RNA interference of the 32 genes in JIMT-1. SKBR3 and JIMT-1 following 48 hr culture in 10 μg/ml trastuzumab.
This demonstrates that in 27 genes, Herceptin sensitivity is restored in JIMT-1 cells after siRNA treatment of each genes.
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antineoplastic mechanism of Herceptin is inhibition of DNA repair,
consistent with the activities of RAD51 and CHEK2 in facilitating
cell cycle inhibition and repair of DNA double-strand breaks
[44]. Moreover, ENAH is a facilitator of the epidermal-to-
mesenchymal transition (EMT), a phenomenon [54] strongly
implicated in Herceptin resistance [3,15]. Similarly, ENAH and
FARP2 in particular are involved in cytoskeleton remodeling, an
event essential for cell motility and metastasis [45,46], in agree-
ment with our identiﬁcation of KEGG pathway hsa04810 (regulation
of actin cytoskeleton), another hallmark of EMT [55]. Interest-
ingly, members of the insulin-like growth factor family, another
contributor to EMT [55], were examined as trastuzumab resis-
tancemarkers in a phase I clinical trial (http://www.clinicaltrials.gov)
[3].
In summary, our now-established subpathway identiﬁcation ap-
proach is highly effective for accurate pathologic biomarker and
pathway discovery. Further retrospective and prospective study of
these resistance-associated pathways and gene products will provide
greater insight into breast cancer signal transduction and the pos-
sible prediction (and perhaps, reversal) of resistance to targeted
therapies such as trastuzumab.
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